Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division
August 30, 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND Fourth FDA Division to Clear TSC IND CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion...
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update
August 11, 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
Reports Improved Outcomes in Phase 1b COVID-19 Study and Positive Trend in Peripheral Oxygenation in Phase 1b TCOM StudyExpects to Announce Initial Indication and Regulatory Pathway in Fourth Quarter...
Growing Demand for Artificial Respiration Systems During COVID-19 Pandemic to Boost the Growth of the Oxygen Cylinder and Concentrator Market and Portable Oxygen Kit Market by 2026 – Exclusive Report By Research Dive
July 26, 2021 09:00 ET
|
Research Dive
New York, USA, July 26, 2021 (GLOBE NEWSWIRE) -- Latest reports on the global oxygen cylinder and concentrator market and global portable oxygen kit market have been added by Research Dive to its...
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
June 30, 2021 07:35 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 10, 2021 07:05 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
March 25, 2021 09:01 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Doses First Participants in TCOM Study
March 18, 2021 07:05 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
March 17, 2021 07:05 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 16:05 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock
February 18, 2021 16:05 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...